Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386996850> ?p ?o ?g. }
- W4386996850 endingPage "2377" @default.
- W4386996850 startingPage "2377" @default.
- W4386996850 abstract "Chemotherapy-induced side effects restrain anti-tumor efficiency, with hyperlipidemia being the most common accompanying disease to cause treatment failure. In this work, a chimeric peptide-engineered nanomedicine (designated as PRS) was fabricated for the synergistic suppression of tumor growth and therapy-induced hyperlipidemia. Within this nanomedicine, the tumor matrix-targeting peptide palmitic-K(palmitic)CREKA can self-assemble into a nano-micelle to encapsulate Rapamycin (mTOR inhibitor) and SBC-115076 (PCSK9 inhibitor). This PRS nanomedicine exhibits a uniform nano-distribution with good stability which enhances intracellular drug delivery and tumor-targeting delivery. Also, PRS was found to synergistically inhibit tumor cell proliferation by interrupting the mTOR pathway and reducing Rapamycin-induced hyperlipidemia by increasing the production of LDLR. In vitro and in vivo results demonstrate the superiority of PRS for systematic suppression of tumor growth and the reduction of hyperlipidemia without initiating any other toxic side effects. This work proposes a sophisticated strategy to inhibit tumor growth and also provides new insights for cooperative management of chemotherapy-induced side effects." @default.
- W4386996850 created "2023-09-25" @default.
- W4386996850 creator A5000601331 @default.
- W4386996850 creator A5004081593 @default.
- W4386996850 creator A5004455301 @default.
- W4386996850 creator A5028072443 @default.
- W4386996850 creator A5038668105 @default.
- W4386996850 creator A5038798689 @default.
- W4386996850 creator A5047717973 @default.
- W4386996850 creator A5057892877 @default.
- W4386996850 creator A5071282511 @default.
- W4386996850 creator A5071289091 @default.
- W4386996850 creator A5076699095 @default.
- W4386996850 creator A5081588668 @default.
- W4386996850 date "2023-09-23" @default.
- W4386996850 modified "2023-10-18" @default.
- W4386996850 title "Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition" @default.
- W4386996850 cites W1252855759 @default.
- W4386996850 cites W2019624593 @default.
- W4386996850 cites W2032751670 @default.
- W4386996850 cites W2035020230 @default.
- W4386996850 cites W2062689336 @default.
- W4386996850 cites W2081001413 @default.
- W4386996850 cites W2089605820 @default.
- W4386996850 cites W2122624068 @default.
- W4386996850 cites W2125223279 @default.
- W4386996850 cites W2133422448 @default.
- W4386996850 cites W2137582107 @default.
- W4386996850 cites W2138185049 @default.
- W4386996850 cites W2143112776 @default.
- W4386996850 cites W2144323242 @default.
- W4386996850 cites W2144516660 @default.
- W4386996850 cites W2150114242 @default.
- W4386996850 cites W2152826474 @default.
- W4386996850 cites W2153867442 @default.
- W4386996850 cites W2160042784 @default.
- W4386996850 cites W2163969089 @default.
- W4386996850 cites W2164089346 @default.
- W4386996850 cites W2164895949 @default.
- W4386996850 cites W2237893739 @default.
- W4386996850 cites W2296515391 @default.
- W4386996850 cites W2325424191 @default.
- W4386996850 cites W239167367 @default.
- W4386996850 cites W2594300836 @default.
- W4386996850 cites W2596179513 @default.
- W4386996850 cites W2766784925 @default.
- W4386996850 cites W2775764871 @default.
- W4386996850 cites W2800400752 @default.
- W4386996850 cites W2888677361 @default.
- W4386996850 cites W2899997727 @default.
- W4386996850 cites W2901242178 @default.
- W4386996850 cites W2912656088 @default.
- W4386996850 cites W2929205901 @default.
- W4386996850 cites W2970625233 @default.
- W4386996850 cites W2999536665 @default.
- W4386996850 cites W3096585654 @default.
- W4386996850 cites W3097142373 @default.
- W4386996850 cites W3103804121 @default.
- W4386996850 cites W3113691894 @default.
- W4386996850 cites W3119152296 @default.
- W4386996850 cites W3131664546 @default.
- W4386996850 cites W3150450748 @default.
- W4386996850 cites W3159086351 @default.
- W4386996850 cites W3160169403 @default.
- W4386996850 cites W3204010869 @default.
- W4386996850 cites W3205769256 @default.
- W4386996850 cites W3208805822 @default.
- W4386996850 cites W4224293098 @default.
- W4386996850 cites W4305014652 @default.
- W4386996850 cites W4306160369 @default.
- W4386996850 cites W4313475622 @default.
- W4386996850 cites W4328115916 @default.
- W4386996850 cites W4378781460 @default.
- W4386996850 cites W4382795555 @default.
- W4386996850 doi "https://doi.org/10.3390/pharmaceutics15102377" @default.
- W4386996850 hasPublicationYear "2023" @default.
- W4386996850 type Work @default.
- W4386996850 citedByCount "0" @default.
- W4386996850 crossrefType "journal-article" @default.
- W4386996850 hasAuthorship W4386996850A5000601331 @default.
- W4386996850 hasAuthorship W4386996850A5004081593 @default.
- W4386996850 hasAuthorship W4386996850A5004455301 @default.
- W4386996850 hasAuthorship W4386996850A5028072443 @default.
- W4386996850 hasAuthorship W4386996850A5038668105 @default.
- W4386996850 hasAuthorship W4386996850A5038798689 @default.
- W4386996850 hasAuthorship W4386996850A5047717973 @default.
- W4386996850 hasAuthorship W4386996850A5057892877 @default.
- W4386996850 hasAuthorship W4386996850A5071282511 @default.
- W4386996850 hasAuthorship W4386996850A5071289091 @default.
- W4386996850 hasAuthorship W4386996850A5076699095 @default.
- W4386996850 hasAuthorship W4386996850A5081588668 @default.
- W4386996850 hasBestOaLocation W43869968501 @default.
- W4386996850 hasConcept C134018914 @default.
- W4386996850 hasConcept C15083742 @default.
- W4386996850 hasConcept C155672457 @default.
- W4386996850 hasConcept C171250308 @default.
- W4386996850 hasConcept C185592680 @default.
- W4386996850 hasConcept C192562407 @default.